Journey Medical Q3 Revenue Rises 8% as Emrosi Sales Jump 84%
DERM is trading near its 52-week low of $4.25 (2.4% above the low).
Summary
Journey Medical posted Q3 2026 total revenue of $19.0 million, up 8% from $17.6 million a year ago, though the result missed estimates, with its lead rosacea drug Emrosi generating $9.0 million, an 84% year-over-year increase. Gross margin improved to 69% from 67%, and the GAAP net loss narrowed to $1.3 million, or $(0.05) per share, from a $2.3 million loss a year earlier. The company reported positive EBITDA and Adjusted EBITDA of $3.5 million for the quarter, a swing from $1.4 million a year ago, though SG&A included a one-time $1.7 million vendor dispute settlement. Cash stood at $22.3 million at September 30, down from $24.1 million at year-end 2025, and the balance sheet carries a $7.5 million short-term term loan plus $18.1 million long-term. This follows the Q2 10-Q filed August 12 that flagged going concern and debt repayments starting in 2027; the improving Emrosi trend and positive EBITDA are the key data points against that backdrop. Fortress Biotech (FBIO) is the founder and controlling shareholder of Journey Medical, so the read-through is indirect for FBIO. Management's conference call is today at 4:30 p.m. ET.
At the time of this announcement, DERM was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.9M. The 52-week trading range was $4.25 to $9.56. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.